- Datum16.05.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
XTB
Jens Klatt
Moderator
Castle Biosciences Inc Aktie
Verkaufen
Kaufen
Castle Biosciences Inc Chart
Castle Biosciences Inc Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,98 %
Intraday
-1,82 %
1 Woche
-22,48 %
1 Monat
-38,16 %
Seit Jahresbeginn
-31,96 %
1 Jahr
-15,40 %
3 Jahre
-55,99 %
5 Jahre
Passender Service zu Castle Biosciences Inc
Webinar zu Castle Biosciences Inc
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)15,700-35,840
- Jahrestief / Hoch ($)15,700-32,740
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Castle Biosciences Inc
Keine Dividenden verfügbar
Termine von Castle Biosciences Inc
Keine aktuellen Termine
Beschreibung
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
